Loading stock data…
CHRS
$1.80+0.02 (+1.41%)
Market ClosedLast close May 1
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Coherus Oncology, Inc. in the Healthcare sector is trading at $1.80. The stock is currently 31% below its 52-week high of $2.62, remaining 19.2% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why CHRS maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.80
Potential Upside
5%
Whystock Fair Value$1.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$263.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
294.61%
Volume
Today's trading volume
560,694
Recent News
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected
Coherus Oncology Inc. (NASDAQ:CHRS) is one of the 10 best penny stocks that could triple your money. On March 10, Coherus Oncology Inc. (NASDAQ:CHRS) reported its fourth quarter EPS of (34c) above the street consensus of (31c), while revenue came in at $12.8 million versus $14.1 million expected. The company highlighted strong progress in 2025, […]
Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk
The latest update keeps Coherus Oncology’s model fair value at US$6.75 per share, even as underlying assumptions around growth and risk have shifted. Some analysts who are more optimistic point to the reaffirmed target as a sign of confidence in the company’s ability to turn its oncology focus into future revenue. In contrast, more cautious voices highlight how much execution now needs to line up with the story. Below, you will see how to track these moving pieces and what to watch as the...
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.